Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern

Nucleic Acid Therapeutics

Volumn 23, Issue 5, 2013, Pages 302-310

  Hagedorn, Peter H ^a   Yakimov, Victor ^b   Ottosen, Søren ^a   Kammler, Susanne ^a   Nielsen, Niels F ^a   Høg, Anja M ^a   Hedtjärn, Maj ^a   Meldgaard, Michael ^a   Møller, Marianne R ^a   Ørum, Henrik ^a   Koch, Troels ^a   Lindow, Morten ^a,b  

^a Santaris Pharma AS   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; DINUCLEOTIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE INSERTION; HISTOPATHOLOGY; LIVER NECROSIS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE ANALYSIS; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ALGORITHMS; ANIMALS; BODY WEIGHT; DRUG DESIGN; FEMALE; LIVER; MICE; MICE, INBRED C57BL; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SIZE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84883404077     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0436     Document Type: Article

References (35)

1. BENNETT, C.F., and SWAYZE, E.E. (2010). RNA targeting therapeutics: Molecular mechanisms of antisense oligonucle-otides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293.
2. BENIGNI, R., and GIULIANI, A. (2003). Putting the predictive toxicology challenge into perspective: Reflections on the results. Bioinformatics 19, 1194-1200.
3. BREIMAN, L. (2001). Random forests. Mach. Learn. 45, 5-32.
4. BUREL, S., and HENRY, S. (2010). Compounds and methods for modulating toxic and proinflammatory effects. Patent. International publication number WO2010108035A1.
5. DUDA, R.O., HART, P.E., and STORK, D.G. (2001). Pattern Classification, 2nd ed., ( John Wiley, New York), pp. 394-443.
6. DURBIN, R., EDDY, S. R., KROGH, A., and MITCHISON, G. (1998). Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids. (Cambridge University Press, Cambridge, UK), pp. 46-79.
7. ELMÉ N, J., LINDOW, M., SILAHTAROGLU, A., BAK, M., CHRISTENSEN, M., LIND-THOMSEN, A., HEDTJÄRN, M., HANSEN, J.B., HANSEN, H.F., STRAARUP, E.M., et al. (2008). Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153-1162.
8. GUPTA, N., FISKER, N., ASSELIN, M.-C., LINDHOLM, M.W., ROSENBOHM, C., ØRUM, H., ELMÉ N, J., SEIDAH, N.G., and STRAARUP, E.M. (2010). A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 5, e10682.
9. HENRY, S., STECKER, K., BROOKS, D., MONTEITH, D., CONKLIN, B. and BENNETT, C.F. (2000). Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292, 468-479.
10. HENRY, S.P., KIM, T.-W., KRAMER-STICKLUND, K., ZANARDI, T.A., FEY, R.A., and LEVIN, A.A. (2007). Toxicologic properties of 2¢-O-methoxyethyl chimeric antisense inhibitors in animals and man. In: S. T. Crooke, Antisense Drug Technology. (CRC Press, Boca Raton, FL), pp. 327-365.
11. HERT, J., IRWIN, J.J., LAGGNER, C., KEISER, M.J., and SHOICHET, B.K. (2009). Quantifying biogenic bias in screening libraries. Nature Chem. Biol. 5, 479-483.
12. HILDEBRANDT-ERIKSEN, E.S., AARUP, V., PERSSON, R., HANSEN, H.F., MUNK, M.E. and ØRUM, H. (2012). A locked nucleic acid oligonucleotide targeting microRNA 122 is well tolerated in cynomolgus monkeys. Nucleic Acid Ther. 22, 152-161.
13. JANSSEN, H.L., REESINK, H.W., LAWITZ, E.J., ZEUZEM, S., RODRIGUEZ-TORRES, M., PATEL K., VAN DER MEER, A. J., PATICK, A. K., CHEN, A., ZHOU, Y., et al. (2013). Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694.
14. KOSHKIN, A.A., SINGH, S.K., NIELSEN, P., RAJWANSHI, V.K., KUMAR, R., MELDGAARD, M., OLSEN, C.E. and WENGEL, J. (1998). LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630.
15. KRIEG, A.M. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484.
16. LEE, J.E., and COOPER, T.A. (2009). Pathogenic mechanisms of myotonic dystrophy. Biochem. Soc. Trans. 37, 1281-1286.
17. LEVENSHTEIN, V.I. (1966). Binary codes capable of correcting deletions, insertions, and reversals. Soviet Phys. Dokl. 10, 707-710.
18. LEVIN, A.A. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
19. LINDHOLM, M.W., ELMÉ N, J., FISKER, N., HANSEN, H.F., PERSSON, R., MøLLER, M.R., ROSENBOHM, C., øRUM, H., STRAARUP, E.M. and KOCH, T. (2012). PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther. 20, 376-381.
20. LINDOW, M., VORNLOCHER, H.-P., RILEY, D., KORNBRUST, D.J., BURCHARD, J., WHITELEY, L.O., KAMENS, J., THOMPSON, J.D., NOCHUR, S., YOUNIS, H., et al. (2012). Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat. Biotechnol. 30, 920-923.
21. LIPINSKI, C.A., LOMBARDO, F., DOMINY, B.W., and FEENEY, P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26.
22. LIPINSKI, C.A., and HOPKINS, A.L. (2004). Navigating chemical space for biology and medicine. Nature 432, 855-861.
23. LOW, Y., UEHARA, T., MINOWA, Y., YAMADA, H., OHNO, Y., URUSHIDANI, T., SEDYKH, A., MURATOV, E., KUZ-MIN, V., FOURCHES, D., et al. (2011). Predicting druginduced hepatotoxicity using QSAR and toxicogenomics approaches. Chem. Res. Toxicol. 24, 1251-1262.
24. OBIKA, S., NANBU, D., HARI, Y., MORIO, K.-I., IN, Y., ISHIDA, T., and IMANISHI, T. (1997). Synthesis of 2¢-O,4¢-Cmethyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering. Tetrahedron Lett. 38, 8735-8738.
25. PETERS, T.S. (2005). Do preclinical testing strategies help predict human hepatotoxic potentials?. Toxicol. Pathol. 33, 146-154.
26. PLATT, J.C. (1999). Probabilistic outputs for support vector machines and comparisons to regularized likelihood methods. In: A. Smola, A.,Bartlett, P., Schölkopf, B., and Shuurmans, D., eds., Advances in Large Margin Classifiers. (MIT Press, Cambridge, MA).
27. RIGO, F., HUA, Y., CHUN, S.J., PRAKASH, T.P., KRAINER, A.R., and BENNETT, C.F. (2012). Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat. Chem. Biol. 8, 555-561.
28. SCHUBERT, D., LEVIN, A. A., KORNBRUST, D., BERMAN, C. L., CAVAGNARO, J., HENRY, S., SEGUIN, R., FERRARI, N., and SHREWSBURY, S.B. (2012). The Oligonucleotide Safety Working Group (OSWG). Nucleic Acid Ther. 4, 211-212.
29. SETH, P.P., SIWKOWSKI, A., ALLERSON, C.R., VASQUEZ, G., LEE, S., PRAKASH, T.P., WANCEWICZ, E.V., WITCHELL, D. and SWAYZE, E.E. (2009). Short antisense oligonucleotides with novel 2¢-4¢ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13.
30. STANTON, R., SCIABOLA, S., SALATTO, C., WENG, Y., MOSHINSKY, D., LITTLE, J., WALTERS, E., KREEGER, J., DIMATTIA, D., CHEN, T., et al. (2012). Chemical Modification Study of Antisense Gapmers. Nucleic Acid Ther. 22, 344-359.
31. STEIN, C.A., SUBASINGHE, C., SHINOZUKA, K., and COHEN, J.S. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209-3221.
32. STRAARUP, E.M., FISKER, N., HEDTJÄRN, M., LINDHOLM, M.W., ROSENBOHM, C., AARUP, V., HANSEN, H.F., øRUM, H., HANSEN, J.B.R., and KOCH, T. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38, 7100-7111.
33. SWAYZE, E.E., SIWKOWSKI, A.M., WANCEWICZ, E.V., MIGAWA, M.T., WYRZYKIEWICZ, T.K., HUNG, G., MONIA, B.P., and BENNETT, C.F. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700.
34. SWAYZE, E.E., and SIWKOWSKI, A.M. (2009). Oligomeric compounds composing bicyclic nucleosides and having reduced toxicity. Patent. International publication number WO09124295A2.
35. WANG, R., LAI, L., and WANG, S. (2002). Further development and validation of empirical scoring functions for structurebased binding affinity prediction. J. Comput. Aided Mol. Des. 16, 11-26.